###begin article-title 0
Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 321 326 <span type="species:ncbi:10090">mouse</span>
To understand which signalling pathways become deregulated in breast cancer, it is necessary to identify functionally significant gene expression patterns in the stem, progenitor, transit amplifying and differentiated cells of the mammary epithelium. We have previously used the markers 33A10, CD24 and Sca-1 to identify mouse mammary epithelial cell subpopulations. We now investigate the relationship between cells expressing these markers and use gene expression microarray analysis to identify genes differentially expressed in the cell populations.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
###xml 283 288 <span type="species:ncbi:10090">mouse</span>
###xml 293 298 <span type="species:ncbi:9606">human</span>
Freshly isolated primary mouse mammary epithelial cells were separated on the basis of staining with the 33A10 antibody and an alpha-Sca-1 antibody. The populations identified were profiled using gene expression microarray analysis. Gene expression patterns were confirmed on normal mouse and human mammary epithelial subpopulations and were examined in a panel of breast cancer samples and cell lines.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 61 63 61 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 68 73 68 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 122 124 118 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 163 165 159 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 170 176 166 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 232 234 228 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 309 314 305 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rgs2 </italic>
###xml 390 392 386 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 397 403 393 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 680 685 676 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rgs2 </italic>
###xml 1125 1130 1121 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 714 719 <span type="species:ncbi:10090">mouse</span>
###xml 822 827 <span type="species:ncbi:9606">human</span>
###xml 1221 1226 <span type="species:ncbi:9606">human</span>
Analysis of the separated populations demonstrated that Sca-1- 33A10High stained cells were estrogen receptor alpha (Esr1)- luminal epithelial cells, whereas Sca-1+ 33A10Low/- stained cells were a mix of nonepithelial cells and Esr1+ epithelial cells. Analysis of the gene expression data identified the gene Rgs2 (regulator of G-protein signalling 2) as being highly expressed in the Sca-1- 33A10Low/- population, which included myoepithelial/basal cells. RGS2 has previously been described as a regulator of angiotensin II receptor signalling. Gene expression analysis by quantitative real-time RT-PCR of cells separated on the basis of CD24 and Sca-1 expression confirmed that Rgs2 was more highly expressed in mouse myoepithelial/basal mammary cells than luminal cells. This expression pattern was conserved in normal human breast cells. Functional analysis demonstrated RGS2 to be a modulator of oxytocin receptor signalling. The potential significance of RGS2 expression in breast cancer was demonstrated by semi-quantitative RT-PCR analysis, data mining and quantitative real-time RT-PCR approaches, which showed that RGS2 was expressed in the majority of solid breast cancers at much higher levels than in normal human mammary cells.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 192 197 192 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
Molecular analysis of prospectively isolated mammary epithelial cells identified RGS2 as a modulator of oxytocin receptor signalling, which is highly expressed in the myoepithelial cells. The RGS2 gene, but not the oxytocin receptor, was also shown to be over-expressed in the majority of breast cancers, identifying the product of this gene, or the pathway(s) it regulates, as potentially significant therapeutic targets.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 338 339 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 340 341 340 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 525 526 525 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 527 528 527 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 529 530 529 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 531 532 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 199 204 <span type="species:ncbi:9606">human</span>
Signal transduction pathways are commonly dysregulated in breast cancer. Estrogen receptor signalling is the best characterised aberrant signalling pathway in the disease [1], but others include the human epidermal growth factor receptor (HER)2, epidermal growth factor receptor (EGFR), prolactin receptor and oxytocin receptor pathways [2-7]. A striking feature of these receptors and their downstream pathways is that they are important determinants of the growth, development and function of the normal breast epithelium [3,4,8,9]. It is likely that the competence of mammary epithelial cells to respond to these signalling pathways in normal development leads to selective pressure to recruit these molecules into the process of tumourigenesis. Understanding the molecular mechanisms that underlie normal cell growth and functional differentiation in the normal mammary gland is therefore critical to developing new therapeutic approaches that target these signalling pathways. A key step in developing such an understanding must be knowledge of genes expressed in the different cellular compartments of the mammary epithelium and their relationship to the function(s) of that compartment.
###end p 11
###begin p 12
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 783 785 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 10 15 <span type="species:ncbi:10090">mouse</span>
###xml 214 219 <span type="species:ncbi:9606">human</span>
The adult mouse mammary epithelium consists of a network of ducts together with (in the pregnant/lactating gland) milk-producing alveoli, the latter being equivalent to the terminal ductal lobulo-alveolar units in human [10]. Both of these structures consist of two basic cell layers: an inner luminal epithelial layer and an outer basal epithelial layer. Luminal cells line the ducts, form the differentiated milk-secreting cells in the alveoli, and are the principal target for estrogen and prolactin. The basal layer is mainly composed of myoepithelial cells, which contract in response to oxytocin released during lactation to force milk from the alveoli down the ducts to the nipple. The basal cell layer also contains the stem cell compartment, which maintains the epithelium [11-14].
###end p 12
###begin p 13
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 483 484 479 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 512 514 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 616 618 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 619 621 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 719 721 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 722 724 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 127 132 <span type="species:ncbi:10090">mouse</span>
###xml 240 245 <span type="species:ncbi:10090">mouse</span>
###xml 397 402 <span type="species:ncbi:10090">mouse</span>
We have previously used a variety of cell surface markers to isolate and characterize these populations. These have included a mouse luminal epithelial milk fat globule membrane antigen (recognized by the 33A10 antibody [15,16]) to isolate mouse mammary luminal epithelial cells [17,18]; CD24 to isolate both basal/myoepithelial and luminal epithelial cells [12,14]; and Sca-1 and Prominin-1 (the mouse homologue of CD133), which both recognize estrogen receptor-alpha positive (Esr1+) luminal epithelial cells [14]. We have shown that the basal epithelial compartment is enriched for epithelial stem cell activity [12,14] and confirmed that this activity can be further purified on the basis of high CD49f expression [13,14]. In our previous studies, however, we confined molecular analysis of these populations to characterizing their function on the basis of expression of genes with known or predicted cell-type specific distributions.
###end p 13
###begin p 14
###xml 355 360 355 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
The aim of the present study, therefore, was to identify genes that have not previously been characterized as being differentially expressed in mammary epithelial cell populations, with particular focus on genes with dysregulated expression in breast cancer. As a result of this analysis we have identified the G-protein coupled receptor (GPCR) regulator RGS2 (which encodes the regulator of G-protein signalling 2 [RGS2]) as being differentially expressed in the various breast epithelial populations. Furthermore, this gene is over-expressed in the majority of breast cancers, making it a potential new target for the development of therapeutics.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
Antibodies
###end title 16
###begin p 17
###xml 5 10 <span type="species:ncbi:10090">mouse</span>
###xml 61 66 <span type="species:ncbi:10090">mouse</span>
###xml 81 84 <span type="species:ncbi:10116">rat</span>
###xml 129 132 <span type="species:ncbi:10116">rat</span>
###xml 243 246 <span type="species:ncbi:10116">rat</span>
###xml 393 396 <span type="species:ncbi:10116">Rat</span>
###xml 402 407 <span type="species:ncbi:10090">mouse</span>
Anti-mouse Sca-1-PE antibody (clone D7; used at 0.1 mug/ml), mouse adsorbed anti-rat IgG-FITC (used at 1 mug/ml) and nonspecific rat IgG control antibodies were obtained from Southern Biotechnology (Cambridge Bioscience, Cambridge, UK). 33A10 rat IgG antibody supernatant (used undiluted) was a kind gift from Professor A Sonnenberg (Netherlands Cancer Institute, Amsterdam, The Netherlands). Rat anti-mouse CD45-PE-Cy5 and CD45-PE-Cy7 (clone 30-F11; used at 0.25 mug/ml) and anti-CD24-FITC (clone M1/69; used at 0.5 mug/mL) were obtained from BD Biosciences (Oxford, UK). Anti-CD24-PE-Cy5 (clone M1/69; used at 0.25 mug/ml) was obtained from Insight Biotechnology (London, UK).
###end p 17
###begin title 18
Plasmids
###end title 18
###begin p 19
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 319 322 319 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 547 550 547 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 560 564 560 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hind</italic>
###xml 724 729 724 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
The RGS2 coding sequence without 5' or 3' untranslated regions was isolated from an IMAGE clone (3681138; Geneservice, Cambridge, UK) in pDNR-LIB by PCR using the primers 5'-GGCTCGAGGCCGCCACCATGCAAAGTGCTATGTTCTTG-3' and 5'-GGCTCGAGTCATGTAGCATGAGGCTC-3'. These primers added a Kozak consensus sequence to the 5' end and XhoI restriction enzyme recognition sites to both ends of the amplified sequence. The PCR product was cloned using the pCR-TOPO-XL kit (Invitrogen, Paisley, UK) and then subcloned from this vector into pcDNA3.1- (Invitrogen) by XhoI digest. HindIII restriction digests indicated plasmids with the RGS2 sequence in the correct orientation (shown by excision of a 510 base pair fragment). Plasmids with the RGS2 insert in the correct orientation were sequence verified.
###end p 19
###begin title 20
Preparation and flow cytometric separation of single mammary cell suspensions
###end title 20
###begin p 21
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 242 244 242 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 288 289 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 406 408 406 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 424 426 424 426 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 528 530 528 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 724 726 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
###xml 367 372 <span type="species:ncbi:10090">mouse</span>
Mammary epithelial organoids were harvested from fourth mammary fat pads of virgin female FVB mice aged 10 to 12 weeks and processed to single cells as previously described [12]. For anti-Sca-1/33A10/anti-CD24 sorting, cell suspensions (at 106 cells/ml) were stained as detailed in Table 1. Staining and sorting with anti-CD24-FITC and anti-Sca-1-PE for isolation of mouse mammary basal/myoepithelial, Esr1+ luminal and Esr1- luminal cells was carried out as described previously [14]. Analysis and exclusion of dead cells, CD45+ cells and nonsingle cells was carried out as described previously [12]. Nonspecific IgG controls were used for compensation and to set sort gates. Flow cytometry data was analysed using FlowJo [19].
###end p 21
###begin p 22
Multiple staining protocols for flow cytometric analysis of alpha-Sca-1/33A10/alpha-CD45 and alpha-Sca-1/33A10/alpha-CD45/alpha-CD24 stained cells.
###end p 22
###begin p 23
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 76 77 76 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
aAnti-CD45-PE-Cy5 was used for the four-colour protocol not including CD24. bAnti-CD45-PE-Cy7, anti-CD24-PE-Cy5 and the IgG-PE-Cy7 isotype control were only used in the five-colour protocol including CD24 detection. 'Fluorescence minus one (FMO)' controls based on the staining combination used for the experimental sample but in which one antibody was left out and replaced with its isotype control were also used to set sort gates correctly. For simplicity, these have not been shown. Live/Dead cell exclusion used either ToPRO-3 or DAPI (4,6-diamidino-2-phenylindole dihydrochloride).
###end p 23
###begin title 24
Cell culture
###end title 24
###begin p 25
###xml 131 135 <span type="species:ncbi:9913">calf</span>
###xml 219 224 <span type="species:ncbi:10090">mouse</span>
Hs578T cells (Sigma, Poole, Dorset, UK) were cultured in Dulbecco's modified Eagle's medium (Invitrogen) with 10% (vol/vol) foetal calf serum (FCS; PAA Laboratories, Somerset, UK) and 10 mug/mL insulin (Sigma). Primary mouse fibroblasts isolated during the preplating procedure in the mammary cell harvest were cultured in Dulbecco's modified Eagle's medium/10% (vol/vol) FCS for up to 2 weeks before RNA isolation.
###end p 25
###begin title 26
cDNA microarray gene expression analysis on freshly isolated mammary epithelial cells
###end title 26
###begin p 27
###xml 215 217 215 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
###xml 711 713 703 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 718 724 710 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 754 756 746 748 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 761 767 753 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 799 801 791 793 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 806 811 798 803 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 471 476 <span type="species:ncbi:10090">mouse</span>
Cells were freshly isolated from mammary tissue, with no intervening culture period, and sorted into sterile screw-cap eppendorf tubes. After sorting, cells were pelleted by spinning in a benchtop centrifuge at 700 g for 5 minutes. Phosphate-buffered saline (PBS) supernatant was aspirated and cell pellets resuspended in 800 mul Trizol reagent (Invitrogen). Where necessary, multiple pellets of the same population were pooled in the 800 mul volume. Cultures of primary mouse mammary fibroblasts were washed in PBS and then scraped into Trizol. Samples were stored at -80degreesC until required for RNA extraction. Total RNA was extracted according to the manufacturers' instructions from two independent Sca-1+ 33A10Low/- samples, two independent Sca-1- 33A10Low/- samples, three independent Sca-1- 33A10High samples, and four independent mammary fibroblast samples. Quality and quantity of the total RNA was assessed using an RNA 6000 nano chip on the Agilent Bioanalyzer (Agilent Technologies UK Limited, Stockport, Cheshire, UK). One hundred nanograms of total RNA was amplified using the AminoAllyl MessageAmp aRNA kit (Ambion, Huntingdon, UK), in accordance with the manufacturer's protocol.
###end p 27
###begin p 28
###xml 131 133 131 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Reference RNA was generated from a pool of RNAs extracted from three mammary cell preparations harvested and sorted to exclude CD45+ cells only. This total RNA pool was amplified using the same technique. Five micrograms of amino allyl aRNA from both test and reference RNA were coupled with either Cy3 or Cy5 fluorochromes (GE Healthcare, Buckinghamshire, UK) and purified with an AminoAllyl MessageAmp aRNA kit (Ambion).
###end p 28
###begin p 29
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 115 120 <span type="species:ncbi:10090">mouse</span>
###xml 168 173 <span type="species:ncbi:10090">Mouse</span>
Dye-labelled test and reference aRNA were co-hybridised on to an in-house (Breakthrough Breast Cancer Centre) cDNA mouse microarray containing 13,825 features (NIA 15K Mouse cDNA clone set) [20,21]. Slides were incubated in a 42degreesC hybridization oven for 16 hours. Washes performed once in 2x sodium chloride/citrate (SSC) and 0.1% (w/v) SDS for 15 minutes, followed by three washes in 0.1 x SSC and 0.1% (weight/vol) SDS for 10 minutes each, and two final washes in 0.1 x SSC for 2 minutes each time. All washes were performed at 65degreesC. Slides were spin dried before scanning.
###end p 29
###begin title 30
Microarray data analysis
###end title 30
###begin p 31
###xml 342 344 342 344 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 541 543 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 634 636 634 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 703 705 703 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 893 894 893 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 898 899 898 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 956 957 956 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 961 962 961 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 992 994 992 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1053 1054 1053 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S5">5</xref>
###xml 1218 1220 1218 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1266 1268 1266 1268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
Each hybridization was performed in duplicate as a dye swap hybridization. Slides were scanned using an Axon 4000B scanner (Axon Instruments, Burlingame, CA, USA) and images were analysed using Genepix Pro 5.1 software (Axon Instruments). Aberrant or distorted spots were removed from analysis. Expression measurements were obtained after log2 transformation of raw intensities and print-tip lowess normalization within each array [22]. Differential gene expression was determined by using the limma package [23] in the R 2.1.1 environment [24] and BioConductor 1.6 [25]. Differentially expressed genes were ranked according to their P value and M ratio, and genes with a false discovery predication of P value < 0.05 were included for further studies [26]. A full list of significantly over-expressed and under-expressed annotated genes from the four populations is given in Additional files 1 to 4. A combined list of all the genes from Additional files 1 to 4, allowing comparisons of the P values across the populations, is given in Additional file 5. The complete datasets, together with unpublished analyses, have been submitted according to MIAME (Minimum Information About a Microarray Experiment) guidelines [27] to the public data repository ArrayExpress [28] with accession number E-MEXP-423.
###end p 31
###begin title 32
Data mining
###end title 32
###begin p 33
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 236 241 236 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 230 235 <span type="species:ncbi:9606">human</span>
The gene expression data from normal luminal epithelial cells, myoepithelial cells and epithelial enriched primary breast cancers were obtained from the reported study by Grigoriadis and coworkers [29]. The expression pattern for human RGS2 was extracted using the Unigene ID Hs.78944 as an identifier.
###end p 33
###begin title 34
Semi-quantitative RT-PCR analysis of cell lines and breast tumour samples
###end title 34
###begin p 35
###xml 670 672 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 745 747 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 952 954 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1020 1022 1018 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1040 1041 1038 1039 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1048 1049 1046 1047 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1112 1114 1110 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1247 1249 1245 1247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1266 1268 1264 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1430 1434 1428 1432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2</italic>
###xml 1436 1441 1434 1439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OXTR </italic>
###xml 1503 1507 1501 1505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 1521 1522 1516 1517 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1611 1616 1604 1609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 1677 1682 1670 1675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OXTR </italic>
###xml 1746 1750 1739 1743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 1916 1921 1909 1914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 1925 1930 1918 1923 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OXTR </italic>
###xml 2072 2077 2065 2070 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 2100 2104 2093 2097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OXTR</italic>
###xml 237 242 <span type="species:ncbi:9606">human</span>
###xml 329 334 <span type="species:ncbi:9606">human</span>
###xml 386 390 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 707 712 <span type="species:ncbi:9606">human</span>
###xml 773 778 <span type="species:ncbi:9606">human</span>
###xml 840 844 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 964 969 <span type="species:ncbi:9606">human</span>
Total RNA (10 mug) from primary samples and cell lines derived from both normal breast and breast cancers was used for each 40 mul reverse transcription reaction. Samples included the following: a normal, immortalized but nontransformed human myoepithelial cell line 1089M (derived from primary myoepithelial cells purified from human reduction mammoplasty tissue and immortalized with SV40 large T-antigen and hTERT, and then subjected to a second round of myoepithelial specific purification; a kind gift from Dr Mike Allen, Queen Mary's School of Medicine and Dentistry, London); a pool of RNA from 10 freshly isolated primary breast luminal epithelial cell samples [29]; immortalized but nontransformed human luminal cell lines 1089L, HB4A [30], 226L33, 226L39 (normal human breast luminal cells immortalized with temperature-sensitive SV40 large T-antigen; a kind gift from Professor Parmjit Jat, Ludwig Institute for Cancer Research) and HBL100 [31]; normal human breast derived endothelial cells and fibroblasts [32]; a panel of ESR1+, ERBB2+, myoepithelial origin and non-estrogen responsive cell lines [33]; and 56 primary breast cancers, of which 20 had been purified to remove F19 antigen-expressing desmoplastic fibroblasts (termed F19- breast cancers) [29]. Unless otherwise stated, samples were a kind gift of Professor Mike O'Hare, Ludwig Institute for Cancer Research. To determine the expression in this panel of RGS2, OXTR (encoding oxytocin receptor) and a control house keeping gene B2M (encoding beta2-microglobulin), 10 mul of 1/50 diluted cDNA was used per 30 mul RT-PCR with primers for RGS2 (5'-CGAGGAGAAGCGAGAAAAGA-3' and 5'-TTCCTCAGGAGAAGGCTTGA-3'), OXTR (5'-TTCTTCGTGCAGATGTGGAG-3' and 5'-GGACGAGTTGCTCTTTTTGC-3'), or B2M (5'-ACTCTGCTTAGAATTTGGGG-3' and 5'-CCACAACCATGCCTTACTTT-3'). Absence of contaminating genomic DNA was confirmed by analysis of samples in an Agilent Bioanalyser. The RGS2 and OXTR primers were designed such that they spanned one or more intron-exon boundaries and would give bands of the expected size (150 base pairs for RGS2 and 233 base pairs for OXTR) only when amplifying from cDNA not from genomic DNA.
###end p 35
###begin p 36
###xml 114 118 114 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2</italic>
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OXTR</italic>
###xml 138 141 138 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M</italic>
###xml 354 359 336 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 466 468 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 510 515 492 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 519 524 501 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OXTR </italic>
RT-PCR was performed by using the Applied Biosystems AmpliTaq Gold (Applied Biosystems, Warrington, UK), with 32 (RGS2), 36 (OXTR) or 25 (B2M) cycles each consisting of 30 seconds at 94degreesC, 30 seconds at 60degreesC, and 45 seconds at 72degreesC. PCR products were visualized on 2% (weight/vol) agarose E-Gels 96 Gels (Invitrogen). An IMAGE clone of RGS2 (3681138) and cDNA made from RNA isolated from Hs578T cells, which express a functional oxytocin receptor [34], were used as positive controls for the RGS2 and OXTR PCRs, respectively.
###end p 36
###begin title 37
Quantitative PCR analysis
###end title 37
###begin p 38
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 133 138 133 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Esr1 </italic>
###xml 168 173 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Prlr </italic>
###xml 195 197 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 300 301 296 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 347 352 343 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rgs2 </italic>
###xml 432 437 428 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 606 612 602 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 897 899 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 341 346 <span type="species:ncbi:10090">mouse</span>
###xml 426 431 <span type="species:ncbi:9606">human</span>
###xml 556 561 <span type="species:ncbi:10090">mouse</span>
###xml 565 570 <span type="species:ncbi:9606">human</span>
###xml 651 656 <span type="species:ncbi:10090">mouse</span>
###xml 676 681 <span type="species:ncbi:9606">human</span>
Quantitative real time PCR (qPCR) reactions were carried out as described previously [14] to determine fold changes in expression of Esr1 (estrogen receptor-alpha) and Prlr (prolactin receptor) [14] in mammary epithelial cell subpopulations compared with a leucocyte-depleted, bulk mammary cell (CD45-) comparator sample. For qPCR assays on mouse Rgs2 (Unigene ID Mm.28262; Taqman Assays on Demand reference Mm00501385_m1) or human RGS2 (Unigene ID Hs. 78944; Taqman Assays on Demand reference Hs00180054_m1), fold changes in expression were compared with mouse or human mammary fibroblasts. In all cases, GAPDH (Taqman Assays on Demand reference for mouse Mm99999915_g1, for human Hs00266705_g1) was used as an internal control. Data were expressed as mean fold changes across samples together with 95% confidence intervals. Significance was determined by comparing confidence interval overlaps [35].
###end p 38
###begin p 39
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 308 313 <span type="species:ncbi:9606">human</span>
Analysis of normal primary human cells was carried out on two pools of RNA from freshly isolated normal myoepithelial cells and two pools of RNA from freshly isolated normal luminal cells (a kind gift of Professor Mike O'Hare). Each cell pool was derived from at least 10 separate isolates of normal primary human breast cells. Each of the myoepithelial pools was analyzed in duplicate, using two separate cDNA syntheses. One luminal pool was analysed in duplicate and one in triplicate with separate cDNA syntheses. Analysis of cell lines and tumour samples was carried out on a selection of the samples described above.
###end p 39
###begin title 40
Transfections
###end title 40
###begin p 41
###xml 76 78 76 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 346 351 346 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 688 693 688 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLK1 </italic>
###xml 843 848 843 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 340 345 <span type="species:ncbi:9606">human</span>
For small interfering (si)RNA analysis, Hs578T cells were seeded at 1.4 x 105 cells per well in six-well plates (Falcon; BD Biosciences) in antibiotic-free medium. The following day, cells were transfected with either an siControl#1 (siCON) siRNA (D-001210-01; Dharmacon, Perbio Science Belgium, Erembodegem, Belgium) or an siRNA targeting human RGS2 (Hs_RGS2_1_HP siRNA; Qiagen, Crawley, West Sussex, UK; siRGS2) using Lipofectamine reagent (Invitrogen), in accordance with the manufacturer's instructions. The response of the cells to oxytocin stimulation (see below) was measured 48 hours later. As a transfection control, additional cells were transfected with an siRNA targeting the PLK1 (polo-like kinase 1) gene (hs_PLK1_6_HP; Qiagen), which is lethal (Lord C, Ashworth A, unpublished data). To confirm gene silencing, qPCR analysis of RGS2 expression levels in siCON versus siRGS2 transfected wells was carried out.
###end p 41
###begin p 42
###xml 88 91 88 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pvu</italic>
To establish cell lines stably over-expressing RGS2, Hs578T cells were transfected with PvuI-linearized pcDNA3.1-RGS2, empty pcDNA3.1- or mock transfected, using Lipofectamine 2000 (Invitrogen), in accordance with the manufacturer's instructions. After 48 hours, cells were selected with 0.5 mg/ml Genetecin (Invitrogen), sufficient to select completely against nontransfected cells. The mock transfected cells all died, but multiple colonies survived in the transfected cultures. The cell lines were maintained as polyclonal populations, under Genetecin selection, to minimize potential variation due to plasmid integration effects.
###end p 42
###begin title 43
Oxytocin receptor activity assays
###end title 43
###begin p 44
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 248 251 248 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7 </sup>
###xml 258 263 258 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 283 286 283 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7 </sup>
###xml 293 298 293 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 780 782 780 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
###xml 1772 1774 1764 1766 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
To assess oxytocin receptor signalling to the downstream p44/42 mitogen-activated protein kinase (MAPK) pathway [36], control and transfected cells in six-well plates were serum and insulin starved for 2 hours and then stimulated with either 1 x 10-7 mol/l (RGS2 silencing) or 5 x 10-7 mol/l (RGS2 over-expression) oxytocin (Sigma) for varying times up to 2 hours. At each time point, medium was removed, the cells were washed with cold PBS and then scraped into 0.5 ml cold lysis buffer (50 mmol/l Tris [pH 7.4], 5 mmol/l EDTA, 150 mmol/l NaCl, 1% Igepal, 2 mmol/l DTT, 1:100 protease inhibitor cocktail, 1:100 phosphatase inhibitor cocktail 1, and 1:100 phosphatase inhibitor cocktail 2; all reagents from Sigma). Samples were lysed on ice for 20 minutes and then spun at 25000 g in a benchtop centrifuge for 10 minutes at 4degreesC. Pelleted insoluble material was discarded and Bradford protein assays carried out on the supernatants. Supernatant samples were mixed with 2 x SDS loading buffer and analysed by SDS-PAGE on 10% polyacrylamide gels and Western blotting. Sample loading was normalised using the results of the Bradford assays. Blots were probed with antibodies against Phospho-p44/42 MAPK (Thr202/Tyr204; #9101; Cell Signalling Technology, NEB, Hitchin, Herts, UK) and total p44/42 MAPK (#9102; Cell Signalling Technology), in accordance with the manufacturer's instructions. A Typhoon Phosphoimager (GE Healthcare, Buckinghamshire, UK) was used to quantify the intensity of the phosphorylated and total bands. The ratios of the corresponding bands was determined and then the percentage of p44/42 phosphorylation at each timepoint was compared with time 0 (0 minutes). Statistical analysis on the p44/42 phosphorylation levels was carried out using a chi2 method, testing whether the observed level of phosphorylation in the Hs578T-RGS2 cells or siRNA transfected cells treated with oxytocin differed significantly from the expected level of phosphorylation (in the control samples treated with oxytocin) across the timepoints.
###end p 44
###begin p 45
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 213 214 213 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 915 917 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1032 1034 1031 1033 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1035 1036 1034 1035 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 1143 1146 1142 1145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7 </sup>
To assess oxytocin signalling-mediated elevation of intracellular calcium levels, a calcium flux assay based on the Fluo-3/Fura Red system was used [37]. In brief, cells were trypsinized and re-suspended at 5 x 105/ml in room temperature phenol-red-free Leibowitz L15 medium/10% (vol/vol) FCS plus 0.1 mmol/l sulfinpyrazone (Sigma). Fluo-3-AM and Fura Red-AM (Invitrogen) were then added to final concentrations of 1 and 2 mumol/l, respectively. Cells were incubated at room temperature for 30 minutes then washed and resuspended in room temperature phenol-red-free L15/10% FCS plus 0.1 mmol/l sulfinpyrazone plus 1:10,000 DAPI (4,6-diamidino-2-phenylindole dihydrochloride). After a further 30 minutes at room temperature the samples were analyzed on a Becton Dickenson LSRII flow cytometric analyser (Becton Dickenson, Oxford, UK). Dead cells and doublets were gated out of the analysis, as described previously [12], and the ratio of Fluo-3/Fura Red fluorescence was plotted against time. This ratio increases with increasing [Ca2+]i. The fluorescence ratio for each sample was analysed using FlowJo for 60 seconds before addition of 5 x 10-7 mol/l oxytocin, to obtain a baseline value, and then for 150 seconds afterward. To compare samples, mean fluorescence ratios for the baseline readings and for 25 second intervals after stimulus addition were plotted.
###end p 45
###begin title 46
Ethical approval
###end title 46
###begin p 47
###xml 151 156 <span type="species:ncbi:9606">human</span>
Harvest of animal tissue for cell separation was carried out under Schedule 1 of the 1986 Animals (Scientific Procedures) Act. Informed consent to use human material for scientific research was obtained.
###end p 47
###begin title 48
Results
###end title 48
###begin title 49
33A10 and alpha-Sca-1 staining identifies mammary cell populations with distinct gene expression patterns
###end title 49
###begin p 50
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 263 265 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 532 534 528 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 625 627 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 679 681 675 677 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 686 692 682 688 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 714 716 708 710 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 721 726 715 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 751 753 743 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 758 764 750 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 780 782 770 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 900 902 886 888 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 948 950 934 936 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 955 960 941 946 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 73 78 <span type="species:ncbi:10090">mouse</span>
We previously characterized the antibody 33A10 as an exclusive marker of mouse mammary epithelial luminal cells [17,18] and have demonstrated that Sca-1 expression is a marker of estrogen receptor-alpha expressing cells within the luminal epithelial compartment [14]. Therefore, to isolate mammary luminal epithelial cell subpopulations for gene expression analysis, freshly harvested primary mammary cell suspensions were stained with 33A10, anti-Sca-1 and anti-CD45 antibodies, and separated by flow cytometry. Dead cells and CD45+ cells were excluded from the analysis. A typical flow cytometry profile is shown in Figure 1a. Three main cell populations were identified: Sca-1+ 33A10Low/- (14.7 +/- 4.8%), Sca-1- 33A10High (44.3 +/- 8.0%) and Sca-1- 33A10Low/- (25.4 +/- 6.3%; n = 5 independent sorts). Surprisingly, given that 33A10 is a luminal epithelial cell marker and alpha-Sca-1 stains Esr1+ luminal epithelial cells, no substantial Sca-1+ 33A10High population was observed.
###end p 50
###begin p 51
###xml 74 78 74 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 126 128 126 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 273 277 273 277 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 369 371 369 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 376 381 376 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/-</sup>
###xml 388 390 388 390 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 395 400 395 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 409 411 409 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 416 422 416 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 429 433 429 433 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 560 564 558 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Esr1</italic>
###xml 590 594 588 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Prlr</italic>
###xml 616 617 614 615 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 622 628 620 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 629 631 627 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 653 655 651 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 660 665 658 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 666 668 664 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 766 768 764 766 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 787 789 785 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 944 946 942 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 194 199 <span type="species:ncbi:10090">mouse</span>
Isolation and characterisation of mammary epithelial cell subpopulations. (a) Flow cytometric staining profiles (dead and CD45+ cells excluded) of anti-Sca-1 and 33A10 stained, freshly isolated mouse mammary cell preparations together with nonspecific IgG-stained control. (b) Graphical space representation of principal component analysis of mammary fibroblasts, Sca-1+ 33A10Low/-, Sca-1- 33A10High and Sca-1- 33A10Low/- cells. (c) Mean fold differences +/- 95% confidence limits in RNA abundance measured by quantitative real-time PCR for estrogen receptor (Esr1) and prolactin receptor (Prlr) transcripts in Sca-1+33A10Low/- (n = 5 samples) and Sca-1- 33A10High (n = 3 samples) mammary subpopulations compared with bulk mammary cell preparations depleted for CD45+ cells (comparator; n = 3 samples). The dotted lines indicate the 95% confidence limits of the comparator sample. All samples show a significant difference to the comparator (**P < 0.01) [35].
###end p 51
###begin p 52
###xml 14 16 14 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 21 26 21 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/-</sup>
###xml 33 35 33 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 40 45 40 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 54 56 54 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 61 67 61 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 225 227 225 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 453 454 453 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 595 596 595 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 695 696 695 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S5">5</xref>
Isolated Sca-1+ 33A10Low/-, Sca-1- 33A10High and Sca-1- 33A10Low/- cells were used to generate gene expression profiles for each of these subpopulations, compared with a reference sample consisting of pooled bulk mammary CD45- cell preparations. In addition, gene expression patterns in mammary fibroblasts, isolated by differential plating during the cell preparation procedure, were also compared with the same reference sample. Additional files 1 to 4 list the well annotated differentially expressed genes significantly increased and decreased in the four populations compared with bulk CD45+-depleted mammary cells according to limma (false discovery rate method) analysis. Additional file 5 compares gene expression in all four populations.
###end p 52
###begin p 53
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 180 182 180 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 187 192 187 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 256 258 256 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 263 269 263 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 282 284 282 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 289 295 289 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
To understand the relationship between the four cell populations, principal component analysis was carried out on the four datasets (Figure 1b). This analysis showed that the Sca-1- 33A10High and fibroblast populations were most distinct, whereas the Sca-1+ 33A10Low/- and the Sca-1- 33A10Low/- populations had the greatest similarity. However, none of the populations clustered together, confirming that the flow cytometric separation did indeed isolate three largely separate populations, which themselves are all different to the mammary fibroblasts.
###end p 53
###begin p 54
###xml 25 27 25 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 32 38 32 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 67 69 67 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 219 224 215 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Prlr </italic>
###xml 228 232 224 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Esr1</italic>
###xml 258 260 254 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 265 271 261 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 280 282 276 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 287 292 283 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 319 321 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 346 348 342 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 353 359 349 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 390 395 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Prlr </italic>
###xml 399 404 395 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Esr1 </italic>
###xml 429 431 425 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 436 441 432 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
To confirm that the Sca-1+ 33A10Low/- population included the Sca-1+ hormone receptor-expressing luminal epithelial cells that we previously identified [14], qPCR for the prolactin receptor and estrogen receptor-alpha (Prlr and Esr1) was carried out on Sca-1+ 33A10Low/- and Sca-1- 33A10High cells. The results (Figure 1c) demonstrated that Sca-1+ 33A10Low/- cells were indeed enriched for Prlr and Esr1 expression, whereas Sca-1- 33A10High luminal epithelial cells were depleted for expression of these genes.
###end p 54
###begin p 55
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S6">6</xref>
###xml 330 332 330 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 337 342 337 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 600 602 600 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 607 613 607 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 625 627 625 627 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 632 638 632 638 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 868 870 868 870 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 875 881 875 881 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
To characterize the biological processes that may be occurring within each cell type, and therefore to better understand their function, Gene Ontology analysis of the biological processes to which each enriched gene contributes was carried out (Additional file 6). This analysis showed that significant processes elevated in Sca-1- 33A10High cells involved ion and lipid metabolism and transport processes. This was not unexpected for cells of the luminal mammary epithelium. Interestingly, however, phagocytosis was also found to be an important biological process in this cell population. The Sca-1- 33A10Low/- cells, Sca-1+ 33A10Low/- cells and the mammary fibroblasts showed a number of similarities, for instance cell adhesion, proteolysis and peptidolysis, which is consistent with the presence of nonepithelial cells in all three populations. However, the Sca-1- 33A10Low/- cells also had a distinct functional speciality involving genes encoding proteins that are associated with smooth muscle contraction. This was consistent with this population containing myoepithelial cells.
###end p 55
###begin title 56
###xml 5 10 5 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 56 61 56 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 66 68 66 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
33A10High luminal epithelial cells are cognate with CD24High Sca-1- luminal epithelial cells
###end title 56
###begin p 57
###xml 38 40 38 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 45 51 45 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 60 62 60 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 67 73 67 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 161 163 161 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 168 173 168 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 224 226 224 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 234 236 234 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 479 481 479 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 486 491 486 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 621 625 621 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Prlr</italic>
###xml 657 658 657 658 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 664 669 664 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 702 707 702 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 712 714 712 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 724 726 724 726 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 730 732 730 732 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 800 802 800 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 903 905 903 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 906 908 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 909 911 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 732 737 <span type="species:ncbi:10090">mouse</span>
###xml 871 876 <span type="species:ncbi:10090">mouse</span>
The data suggested that both the Sca-1- 33A10Low/- and Sca-1+ 33A10Low/- populations were a mixture of epithelial and nonepithelial cell types, whereas the Sca-1- 33A10High population was a relatively pure population of Esr1- and Prlr- luminal epithelial cells. Only a few genes were found to be upregulated in this population compared with the reference, and only at modest levels, probably as a consequence of the reference population used being itself mainly composed of Sca-1- 33A10High cells. Nevertheless, the genes that were upregulated (for example, that encoding lactotransferrin) or downregulated (for example, Prlr) were consistent with the Sca-1-/33A10High cells being cognate with the CD24High Sca-1- Prominin-1- Esr1- mouse mammary luminal epithelial cells that we recently identified [14]. This contrasted with previous observations that 33A10 stained all mouse luminal epithelial cells [15,17,18].
###end p 57
###begin p 58
###xml 36 38 36 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 43 48 43 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 209 211 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 235 239 227 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low </sup>
###xml 244 246 236 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 296 298 288 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 311 316 303 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 321 323 313 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 328 329 320 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 355 359 347 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High</sup>
###xml 397 402 389 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 407 409 399 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 414 415 406 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 496 501 488 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 506 508 498 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 513 514 505 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 552 556 544 548 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low </sup>
###xml 811 813 803 805 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 821 823 813 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 72 77 <span type="species:ncbi:10090">mouse</span>
###xml 266 271 <span type="species:ncbi:10090">mouse</span>
###xml 608 613 <span type="species:ncbi:10090">mouse</span>
###xml 855 860 <span type="species:ncbi:10090">mouse</span>
To confirm the identity of the Sca-1- 33A10High cells, freshly isolated mouse mammary cell preparations were stained with alpha-CD24, alpha-Sca-1 and 33A10, and analyzed by flow cytometry. The results (Figure 2a) demonstrated that CD24Low Sca-1- basal/myoepithelial mouse mammary cells were 33A10- and that CD24High Sca-1- (Esr1-) luminal cells were 33A10High. The data also demonstrated that CD24High Sca-1+ (Esr1+) luminal cells did in fact stain with 33A10 but to a lesser extent than the CD24High Sca-1- (Esr1-) population, forming a distinct 33A10Low population. This confirmed 33A10 as a marker of all mouse mammary luminal epithelial cells, but it also showed quantitative differences in staining on different luminal epithelial populations. It also confirmed and extended our previous findings that Esr1+ and Esr1- luminal epithelial cells of the mouse mammary gland are distinct epithelial populations.
###end p 58
###begin p 59
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rgs2 </italic>
###xml 32 36 32 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low </sup>
###xml 41 43 41 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 48 50 48 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 122 126 122 126 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 391 395 391 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low </sup>
###xml 400 402 400 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 434 435 434 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 442 447 442 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 452 454 452 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 459 460 459 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 482 486 482 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High</sup>
###xml 496 501 496 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 506 508 506 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 513 514 513 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 536 539 536 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low</sup>
###xml 561 565 561 565 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 638 643 636 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rgs2 </italic>
###xml 655 659 653 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low </sup>
###xml 664 666 662 664 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 691 696 689 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 701 703 699 701 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 708 709 706 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 738 743 736 741 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 748 750 746 748 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 755 756 753 754 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 798 800 796 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 968 970 966 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1051 1056 1049 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rgs2 </italic>
###xml 1111 1115 1109 1113 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 1192 1197 1188 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 1510 1512 1506 1508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1585 1590 1581 1586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
###xml 88 93 <span type="species:ncbi:9606">human</span>
###xml 162 167 <span type="species:ncbi:10090">mouse</span>
###xml 278 281 <span type="species:ncbi:10116">rat</span>
###xml 295 298 <span type="species:ncbi:10116">rat</span>
###xml 322 325 <span type="species:ncbi:10116">rat</span>
###xml 777 782 <span type="species:ncbi:10090">mouse</span>
###xml 1242 1247 <span type="species:ncbi:9606">human</span>
###xml 1275 1280 <span type="species:ncbi:9606">human</span>
Rgs2 is highly expressed in CD24Low Sca-1- 33A10- mouse mammary basal/myoepithelial and human breast myoepithelial cells. (a) Flow cytometric staining profile of mouse mammary cell preparations stained with anti-Sca-1 and anti-CD24 antibodies together with either a nonspecific rat IgG and anti-rat-FITC or 33A10 and anti-rat FITC. The nonspecific IgG and 33A10 staining profiles of the CD24Low Sca-1- basal/myoepithelial cells (33A10-), CD24High Sca-1- (Esr1-) luminal cells (33A10High) and CD24High Sca-1+ (Esr1+) luminal cells (33A10Low) [14] are indicated. (b) Mean fold differences +/- 95% confidence limits in RNA abundance for the Rgs2 gene in CD24Low Sca-1- basal/myoepithelial, CD24High Sca-1- (Esr1-) luminal epithelial and CD24High Sca-1+ (Esr1+) luminal epithelial mouse mammary cells (n = 3 for all samples) [14]. The dotted lines indicate the 95% confidence limits of the comparator sample. All samples show a significant difference to the comparator (**P < 0.01). The basal myoepithelial cells also have a significantly higher level of Rgs2 expression than either of the two luminal populations. (c) Mean fold differences +/- 95% confidence limits in expression levels for the RGS2 gene in myoepithelial and luminal epithelial human breast cells compared with human breast fibroblasts (comparator). See Materials and methods for details of the samples. The dotted lines indicate the 95% confidence limits of the comparator sample. Both samples show a significant difference to the comparator (**P < 0.01) and the myoepithelial cells have a significantly higher level of RGS2 expression than the luminal cells.
###end p 59
###begin title 60
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rgs2 </italic>
Rgs2 is highly expressed in the basal/myoepithelial cells of the mammary gland
###end title 60
###begin p 61
###xml 187 191 183 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rgs2</italic>
###xml 342 343 334 335 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q</sub>
###xml 389 391 381 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 396 402 388 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 411 413 403 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 418 423 410 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 504 506 496 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 511 517 503 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 571 575 563 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low </sup>
###xml 630 635 622 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rgs2 </italic>
###xml 806 810 798 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low </sup>
###xml 815 817 807 809 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 848 853 840 845 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 858 860 850 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 865 866 857 858 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 901 906 893 898 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 911 913 903 905 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 918 919 910 911 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 936 938 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 997 1002 989 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rgs2 </italic>
###xml 1093 1095 1085 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 1112 1117 1104 1109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rgs2 </italic>
###xml 1288 1293 1280 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rgs2 </italic>
###xml 788 793 <span type="species:ncbi:10090">mouse</span>
###xml 1030 1035 <span type="species:ncbi:10090">mouse</span>
The gene expression data was next interrogated for genes significantly differentially regulated within the cell populations identified by 33A10 and alpha-Sca-1 co-staining. We noted that Rgs2, which encodes a small GTPase-activating protein (GAP) that is involved in the negative regulation of signalling from G proteins, in particular Galphaq, was significantly downregulated in the Sca-1+ 33A10Low/- and Sca-1- 33A10High populations, as well as in fibroblasts. However, it was highly expressed in Sca-1- 33A10Low/- cells. As the latter population consisted of both CD24Low basal/myoepithelial cells and nonepithelial cells, but Rgs2 was under-expressed in the fibroblasts, we reasoned that it must be strongly expressed specifically in the basal/myoepithelial population. To test this, mouse mammary CD24Low Sca-1- basal/myoepithelial cells, CD24High Sca-1- (Esr1-) luminal epithelial cells and CD24High Sca-1+ (Esr1+) luminal cells [14] were freshly isolated and qPCR analysis of the levels of Rgs2 mRNA was carried out, using mouse mammary fibroblasts as a comparator. The results (Figure 2b) confirmed that Rgs2 mRNA expression was strongly upregulated in basal/myoepithelial cells compared with the fibroblast comparator population and both luminal epithelial populations. However, Rgs2 expression could still be detected in the luminal epithelial populations.
###end p 61
###begin p 62
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 421 426 421 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 91 96 <span type="species:ncbi:10090">mouse</span>
###xml 250 255 <span type="species:ncbi:9606">human</span>
###xml 447 452 <span type="species:ncbi:9606">human</span>
To determine whether the RGS2 expression pattern in human cells was similar to that of the mouse, we analysed gene expression data from three different microarray platforms (Affymetrix, Agilent and Codelink), comparing pooled RNA from primary normal human myoepithelial and luminal epithelial cells (RNA isolated from 10 different preparations in each pool) [29]. The results did not show significant differences between RGS2 expression in normal human myoepithelial and luminal cells.
###end p 62
###begin p 63
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2c</xref>
###xml 334 339 334 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 461 466 461 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 801 806 801 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 39 44 <span type="species:ncbi:10090">mouse</span>
###xml 127 132 <span type="species:ncbi:9606">human</span>
###xml 197 202 <span type="species:ncbi:9606">Human</span>
###xml 311 316 <span type="species:ncbi:10090">mouse</span>
###xml 522 527 <span type="species:ncbi:9606">human</span>
###xml 566 571 <span type="species:ncbi:9606">human</span>
###xml 653 658 <span type="species:ncbi:10090">mouse</span>
###xml 820 825 <span type="species:ncbi:9606">human</span>
###xml 830 835 <span type="species:ncbi:10090">mouse</span>
Because this result disagreed with the mouse expression data, we used qPCR to better quantify RGS2 expression levels in pooled human normal primary myoepithelial and luminal epithelial cells [29]. Human breast fibroblasts [32] were used as a comparator. This analysis (Figure 2c) demonstrated that, as with the mouse expression data, RGS2 expression could be detected in both myoepithelial and luminal epithelial populations. However, although qPCR showed that RGS2 expression levels were also significantly higher in the human myoepithelial cells compared with the human luminal cells, the differences were modest compared with those observed with the mouse cells. These modest differences could apparently not be detected by the array platforms. These data did confirm, however, that the pattern of RGS2 expression in human and mouse mammary epithelial cells was similar.
###end p 63
###begin title 64
RGS2 is a regulator of oxytocin receptor signalling
###end title 64
###begin p 65
###xml 71 73 67 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q </sub>
###xml 146 148 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 434 436 426 428 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q </sub>
###xml 446 448 434 436 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
###xml 458 460 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 572 577 560 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
RGS2 is a GAP that switches off G-protein activity (particularly Galphaq activity) and therefore acts as a negative regulator of GPCR signalling [38]. To identify potential functions for RGS2 in the breast, candidate GPCR pathways that might be regulated by RGS2 were examined. One good candidate was the oxytocin receptor pathway. The oxytocin receptor is a GPCR related to the vasopressin receptor, which signals through both Galphaq and Galphai subunits [36], and in the breast it is specifically located in the myoepithelium, the same compartment that is enriched for RGS2 expression.
###end p 65
###begin p 66
###xml 76 81 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 332 337 332 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 415 420 415 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
To test whether RGS2 was a regulator of oxytocin signalling, the effects of RGS2 over-expression were examined in Hs578T cells, which have an endogenous, functional oxytocin receptor [34]. We established a pair of cell lines, one of which stably expressed the empty parental vector (Hs578T-pcDNA) whereas the other stably expressed RGS2 (Hs578T-RGS2). qPCR analysis confirmed that the Hs578T-RGS2 line had fivefold RGS2 over-expression compared with the control cell line (Figure 3a).
###end p 66
###begin p 67
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 76 80 76 80 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 119 124 119 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 349 351 347 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 360 365 358 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 454 458 452 456 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 543 546 541 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7 </sup>
###xml 624 628 622 626 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 775 778 773 776 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7 </sup>
###xml 794 798 792 796 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 895 897 893 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
RGS2 overexpression attenuates oxytocin receptor signalling to p44/42 MAPK. (a) quantitative real-time PCR analysis of RGS2 gene expression in triplicate samples of stably transfected Hs578T-pcDNA (parental vector) compared with Hs578T-RGS2 cells. Mean expression levels +/- 95% confidence limits are shown. Significant differences are indicated (**P < 0.01). RGS2 was fivefold overexpressed in the Hs578T-RGS2 cells compared with the control cell line. (b) Analysis of calcium flux in Hs578T-pcDNA and Hs578T-RGS2 cells stimulated with 5 x 10-7 mol/l oxytocin. Both cell lines showed an identical response to the stimulus. (c) Time course analysis of p44/42 mitogen-activated protein kinase (MAPK) phosphorylation in Hs578T-pcDNA and Hs578T-RGS2 cells stimulated with 5 x 10-7 mol/l oxytocin. (d) Quantitation of phosphorylation analysis. p44/42 MAPK phosphorylation was significantly reduced (P < 0.001) in the Hs578T-RGS2 cell line compared with the control Hs578T-pcDNA cells.
###end p 67
###begin p 68
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 664 667 664 667 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7 </sup>
###xml 797 801 797 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c,d</xref>
###xml 836 841 836 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 872 874 872 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Intracellular signalling downstream from the oxytocin receptor is mediated both by calcium signalling [39] and via p44/42 MAPK [36,40]. To determine whether RGS2-regulated calcium signalling downstream of oxytocin receptor activation, a calcium flux assay was carried out on the Hs578T-pcDNA and Hs578T-RGS2 cells. The results (Figure 3b) showed that the calcium flux in these cells following oxytocin stimulation was identical, indicating that RGS2 does not regulate this pathway. Next, p44/42 MAPK phosphorylation in response to oxytocin stimulation in the cell lines was examined. Cells were serum starved and insulin starved for 2 hours, stimulated with 5 x 10-7 mol/l oxytocin and then harvested at different time points for assessment of levels of phosphorylated, active p44/42 MAPK (Figure 3c,d). In two independent experiments, RGS2 over-expression significantly (P < 0.001 in both experiments) reduced p44/42 MAPK phosphorylation after oxytocin stimulation.
###end p 68
###begin p 69
###xml 103 108 103 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 211 216 211 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 284 287 284 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7 </sup>
###xml 414 419 414 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 586 591 586 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 639 641 639 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 729 733 729 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a,b</xref>
###xml 770 775 770 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 805 807 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c</xref>
To confirm this result, we examined the effects on p44/42 MAPK phosphorylation of silencing endogenous RGS2 in wild-type Hs578T cells. Cells transfected with either a control (siCON) siRNA or an siRNA targeting RGS2 (siRGS2) were serum and insulin starved and then treated with 1 x 10-7 mol/l oxytocin. A lower concentration of oxytocin was used to give a reduced stimulation, which could be measurably altered by RGS2 silencing. Again, cells were harvested at different time points and assayed for levels of phospho-p44/42 MAPK. In two independent experiments, silencing of endogenous RGS2 in wild-type Hs578T cells caused a significant (P < 0.001) increase in p44/42 MAPK phosphorylation following oxytocin stimulation (Figure 4a,b). Efficient silencing of endogenous RGS2 was confirmed by qPCR (Figure 4c).
###end p 69
###begin p 70
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 100 104 100 104 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 217 222 217 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 300 303 300 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7 </sup>
###xml 516 520 516 520 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 683 685 683 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 747 751 747 751 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 790 795 790 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 1216 1218 1214 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Silencing of endogenous RGS2 enhances oxytocin receptor signalling via p44/42 MAPK in Hs578T cells. (a) Hs578T cells transfected with either a scrambled control small interfering (si)RNA (SiCON) or an siRNA targeting RGS2 (siRGS) were serum and insulin starved for 2 hours then stimulated with 1 x 10-7 mol/l oxytocin. Cells were harvested at timepoints up to 120 minutes after oxytocin addition and lysates analysed for levels of phospho- and total p44/42 mitogen-activated protein kinase (MAPK) by immunoblotting. (b) Quantitation of siRNA knockdown from two independent transfections. The upper plot is the quantitation of the blots shown in panel a. siRGS2 caused a significant (P < 0.001) increase in phosphorylation in response to oxytocin. (c) Quantitative real-time PCR analysis of RGS2 expression in Hs578T cells transfected with the siRGS2. Each bar represents the mean +/- 95% confidence limits of the fold difference in expression compared with the mean expression in the siCON transfected cells. Data from four samples harvested from two independent transfections is shown (one of which was also used in the lower oxytocin response experiment shown in panel b). Significant differences are indicated (**P < 0.01).
###end p 70
###begin title 71
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
RGS2 is over-expressed in the majority of breast cancers
###end title 71
###begin p 72
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 128 133 128 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 612 617 612 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 742 744 742 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 755 758 755 758 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-10</sup>
###xml 789 791 789 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 802 804 802 804 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 836 838 836 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 849 852 849 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-10</sup>
###xml 885 887 885 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 898 900 898 900 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 996 1001 996 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 58 63 <span type="species:ncbi:9606">human</span>
Finally, we examined the pattern of expression of RGS2 in human breast cancer. A data mining approach was first used to examine RGS2 expression in a set of gene expression data from normal breast samples (10 pooled isolates of freshly separated normal luminal cells) and breast cancers (15 freshly isolated infiltrating ductal carcinomas of grade 2 or 3, from which cells expressing the desmosplastic fibroblast antigen F19 had been removed) analyzed by four different gene expression microarray platforms and massively parallel signature sequencing [29]. The data from all four microarray platforms showed that RGS2 was significantly upregulated in malignant breast cancers compared with normal luminal cells (Affymetrix: 3.2-fold increase, P = 3.77 x 10-10; Agilent: 2.49-fold increase, P = 1.25 x 10-6; CodeLink: 3.02-fold increase, P = 2.14 x 10-10; brk IMAGE: 2.71-fold increase, P = 1.35 x 10-6). The massively parallel signature sequencing analysis quantified the tumour pool as having 96 RGS2 transcripts per million and the normal luminal pool as having 0 transcripts per million (the gene was not detected in two independent sequencing runs).
###end p 72
###begin p 73
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 329 331 329 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 342 345 342 345 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-10</sup>
###xml 376 378 376 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 389 391 389 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
###xml 423 425 423 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 436 438 436 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4</sup>
###xml 78 83 <span type="species:ncbi:9606">human</span>
We next compared expression of RGS2 in the tumour pool with the pooled normal human myoepithelial cells on the Affymetrix, Agilent and Codelink platforms. These data showed that the RGS2 expression was also significantly upregulated in the tumour pool compared with the normal myoepithelial pool (Affymetrix: 3.48-fold increase, P = 2.23 x 10-10; Agilent: 2.85-fold increase, P = 4.71 x 10-5; CodeLink: 12.9-fold increase, P = 1.14 x 10-4).
###end p 73
###begin p 74
###xml 118 120 118 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 340 345 340 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 392 397 392 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OXTR </italic>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 454 464 454 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 479 484 479 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 613 618 613 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OXTR </italic>
###xml 707 709 707 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
To validate these findings, a panel of samples including normal breast cells, breast cancer cell lines (including ESR1+ cell lines, estrogen nonresponsive cell lines, ERBB2 over-expressing cell lines and 55 primary tumour samples, some of which had been depleted of F19-expressing fibroblasts) were analysed by semi-quantitative RT-PCR for RGS2 expression. The samples were also analysed for OXTR expression levels. The results (Figure 5a) confirmed the in silico analysis, with RGS2 expression seen in the majority of samples, being particularly strong in the solid tumour and F19-depleted samples. In contrast, OXTR expression in cell lines and primary tumours was variable, with only two out of four ESR1+ breast cancer cell lines, one of three ERBB2 over-expressing cell lines, one basal origin tumour cell line, eight out of 17 (47%) estrogen nonresponsive cell lines, and 23 out of 56 (41%) primary tumours having detectable oxytocin receptor gene expression.
###end p 74
###begin p 75
###xml 82 86 82 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 284 294 284 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2, OXR </italic>
###xml 318 321 318 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M</italic>
###xml 323 327 323 327 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 575 577 573 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 21 26 <span type="species:ncbi:9606">human</span>
###xml 415 420 <span type="species:ncbi:9606">human</span>
###xml 428 433 <span type="species:ncbi:9606">human</span>
RGS2 is expressed in human myoepithelial and luminal cells and in breast cancers. (a) RNA isolated from normal primary breast cells, normal and breast cancer cell lines and primary breast cancers was analysed by semi-quantitative RT-PCR for expression at the transcriptional level of RGS2, OXR and a housekeeping gene B2M. (b) Quantitative real-time PCR analysis of RGS2 expression levels in a selection of primary human cells, human breast cancer cell lines, solid breast cancers and F19-depleted cancers. Data are mean relative expression levels +/- 95% confidence limits (n = 3 analyses of each sample). For comparison, the primary myoepithelial and primary luminal cell data from Figure 2c have been included on this graph. Note that the y-axis is a log10 scale.
###end p 75
###begin p 76
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 396 401 396 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 511 516 511 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 537 542 537 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 788 793 788 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 872 877 872 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
For more accurate quantitation of levels of RGS2 mRNA expression in cell lines and primary tumours, a selection of cell lines, solid tumours and F19-depleted tumours was examined by qPCR. The results (Figure 5b) showed that compared with normal primary cells (either myoepithelial or luminal epithelial cells, breast fibroblasts, or endothelial cells) most cell lines had a much reduced level of RGS2 expression. One exception was the 1089M immortalized normal myoepithelial cell line, which had high levels of RGS2 expression. However, RGS2 expression was significantly increased in the solid tumours compared with the normal primary cells. It was increased still further in the F19-depleted cancers compared with all samples (including the 1089M cell line), some of which had levels of RGS2 expression 1,000-fold or more times that of the comparator. This suggests that RGS2 mRNA expression is strongly upregulated specifically in the epithelial cells of the majority of primary breast cancers.
###end p 76
###begin title 77
Discussion
###end title 77
###begin p 78
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 300 302 300 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 327 331 327 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low </sup>
###xml 365 370 365 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 415 420 415 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 481 483 481 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 491 493 491 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 497 499 497 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 508 510 508 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 520 522 520 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 526 528 526 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 695 700 695 700 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 705 707 705 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 715 720 715 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 725 727 725 727 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 924 926 924 926 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 931 936 931 936 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 973 978 973 978 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 983 985 983 985 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1190 1192 1190 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1199 1204 1199 1204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 1209 1211 1209 1211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1216 1217 1216 1217 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 1255 1260 1255 1260 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 1289 1294 1289 1294 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 1299 1301 1299 1301 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1306 1307 1306 1307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1344 1347 1344 1347 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low</sup>
###xml 1366 1370 1366 1370 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low </sup>
###xml 1375 1377 1375 1377 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1413 1414 1413 1414 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 1765 1767 1765 1767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1768 1770 1768 1770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 43 48 <span type="species:ncbi:10090">mouse</span>
###xml 595 600 <span type="species:ncbi:10090">mouse</span>
###xml 1612 1617 <span type="species:ncbi:10090">mouse</span>
In our previous studies, we found that the mouse mammary epithelium could be separated into total luminal or myoepithelial fractions by using the 33A10 and JB6 antibodies respectively [17,18], and, more recently, that anti-CD24 staining identifies three distinct mammary cell populations, namely CD24- nonepithelial cells, CD24Low basal/myoepithelial cells and CD24High total luminal epithelial cells [12]. The CD24High total luminal fraction could be further subdivided into Sca-1+ Prominin+ Esr1+ and Sca-1- Prominin-1- Esr1- fractions [14]. In the present study we expected that, because the mouse mammary luminal fraction can be isolated with both 33A10 and anti-CD24 staining, both the CD24High Sca-1+ and CD24High Sca-1- cells would have identical 33A10 staining patterns. Instead, we found that the 33A10 antibody differentially stained the luminal epithelial populations. We were able initially to identify the Sca-1- 33A10High population as being identical to CD24High Sca-1- cells on the basis of patterns of gene expression. Subsequent flow cytometric analysis confirmed that 33A10 staining differentiated between the two luminal epithelial populations we previously identified [14]. CD24High Sca-1- (Esr1-) luminal epithelial cells had a 33A10High staining pattern whereas CD24High Sca-1+ (Esr1+) luminal epithelial cells were 33A10Low. As expected, CD24Low Sca-1- basal/myoepithelial cells were 33A10-. This new differential staining pattern of the 33A10 antibody was most likely observed because of advances in flow cytometry technology and analysis software since our early observations, although mouse strain differences in the pattern of expression of the antigen recognized by the 33A10 antibody (most likely a milk fat globule membrane antigen) [15,16] cannot be excluded.
###end p 78
###begin p 79
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 283 285 283 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 290 295 290 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 318 323 318 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rgs2 </italic>
###xml 434 439 434 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 60 65 <span type="species:ncbi:10090">mouse</span>
With these data, we were able to extend our analysis of the mouse mammary epithelium, confirming that there are two distinct populations of luminal epithelial cells [14]. Furthermore, we used the gene expression array data that formed the basis for defining the identity of the Sca-1- 33A10High population to identify Rgs2 as a gene highly differentially regulated between the epithelial populations of the mammary gland. Remarkably, RGS2 is over-expressed in the majority of breast cancer cell lines and primary breast tumours. RGS2 and the pathways it regulates are therefore important new candidate therapeutic targets for the treatment of breast cancer.
###end p 79
###begin p 80
###xml 157 159 153 155 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q </sub>
###xml 168 170 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 261 263 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 719 721 674 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 878 880 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
RGS2 is a regulator of GPCRs, which acts as a GTPase-activating protein (GAP), primarily (although not exclusively) downregulating signalling from the Galphaq subunit [41]. GPCRs are the largest family of cell-surface molecules involved in signal transduction [42]. They all have a core of seven transmembrane alpha-helices and, after agonist binding, interact with the alphabetagamma G-protein heterotrimers. This catalyzes the dissociation of Galpha-bound GDP and its replacement with GTP, leading to dissociation of the Gbetagamma from the Galpha subunits. The Galpha* GTP and Gbetagamma subunit complexes then both stimulate downstream effectors until the GTP is hydrolyzed back to GDP and the signal switched off [42]. GTP hydrolysis is regulated by the RGS proteins, which act as GAPs for Galpha subunits, although they can also have GAP-independent regulatory functions [43].
###end p 80
###begin p 81
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 336 341 336 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rgs2 </italic>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 735 736 731 732 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 837 839 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 983 985 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 350 354 <span type="species:ncbi:10090">mice</span>
###xml 469 473 <span type="species:ncbi:10090">mice</span>
###xml 858 862 <span type="species:ncbi:10090">mice</span>
The diverse signalling roles of GPCRs in cancer were recently reviewed [42]. In breast cancer, these include potential roles in growth, metastasis, angiogenesis and hormone therapy resistance. Given this diversity, determination of the specific function(s) of RGS2 in the context of the breast and breast cancer is extremely difficult. Rgs2 knockout mice were viable and had normal reproduction, although mammary phenotypes and lactation were not examined [41,44]. The mice did, however, exhibit a hypertensive phenotype, with renovascular abnormalities, persistent constriction of resistance vasculature and prolonged response of vasculature to vasoconstrictors. These effects were mediated through angiotensin II signalling and alpha1-adrenergic receptors and the hypertensive phenotype could be blocked with AT1 receptor antagonists [41]. Analysis of the mice also demonstrated that Rgs2 plays role in T-cell activation, synapse development in hippocampus and emotive behaviours [44]. The involvement of the gene in mediating vascular constriction and its strong over-expression in the basal mammary cell compartment suggested that at least one role for RGS2 in the breast is as a regulator of oxytocin signalling in the mammary gland, regulating myoepithelial cell contraction during lactation. Indeed, the data presented here confirm that RGS2 modulates signalling of the oxytocin receptor to p44/42 MAPK but not oxytocin receptor-mediated calcium signalling, suggesting that it does indeed regulate signalling of this receptor in the myoepithelial cells.
###end p 81
###begin p 82
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 236 241 236 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 245 250 245 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OXTR </italic>
###xml 322 327 322 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 945 950 945 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
Remarkably, RGS2 gene expression was also upregulated in the majority of breast cancers examined, suggesting that dysfunction in the pathway or pathways regulated by RGS2 in the breast is an obligate event in breast cancer development. RGS2 and OXTR expression levels were not correlated in breast cancer, suggesting that RGS2 modulates a different GPCR pathway(s) in breast tumours. Exactly which pathway remains unclear. A number of GPCRs have been previously reported to be overexpressed in breast cancer, including CCR1, Opsin-3, CXCR4, PAR1, PAR2, EP2, EP4, GPR30 and the C3A anaphylatoxin chemotactic receptor [42,45], although whether any of these are regulated by RGS2 remains unknown. One clue to the pathways involved may be that RGS2 was upregulated in the solid breast cancers, and in particular in the F19-depleted cancers, but tended to be less strongly expressed in cancer cell lines than in the normal tissue. This suggests that RGS2 expression in tumours is a consequence of interactions with the tumour microenvironment.
###end p 82
###begin p 83
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 835 843 835 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 1076 1078 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1360 1365 1360 1365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 1442 1444 1442 1444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
Identification of the GPCR pathway(s) regulated by RGS2 in breast cancer will be key to assessing whether it has a critical function in cancer biology and whether this pathway is of value as a therapeutic target. GPCRs can have tumour suppressor activity, as has been noted for GPR54 and metastasis in breast cancer [42], and tumour development would lead to selective pressure to block such pathways. Mechanisms for blocking the activity of tumour suppressor GPCR pathways could include upregulation of negative regulators of GPCRs, such as RGS2. Alternatively, GPCRs can provide cellular proliferation and survival signals [42,46,47], possibly in response to interactions with the tumour microenvironment, and RGS2 upregulation may be the result of a negative feedback mechanism. This would be consistent with its high expression in in situ cancers (Figure 5b). In this case, alternative survival signals might be selected for in tumour development to bypass the RGS2 block. Identifying and blocking alternative survival signals may enable a 'synthetic lethality' approach [48] to treating breast cancers with high levels of RGS2. Such an approach is attractive because direct targeting of RGS2 itself may prove problematic because of possible side effects resulting from its role in the regulation of vasoconstriction. However, the very large difference in RGS2 expression between F19-depleted tumours and normal endothelial cells (Figure 5b) suggests that a pronounced therapeutic window for RGS2 targeting exists.
###end p 83
###begin p 84
###xml 59 61 59 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
Activity of p44/42 MAPK tends to be high in breast cancer [49], and so it is perhaps counterintuitive that RGS2, which suppresses p44/42 MAPK phosphorylation in oxytocin signalling, is highly expressed in breast cancers and cancer cell lines. However, RGS2 acts at the level of the G protein in the signalling pathway, not on p44/42 MAPK itself. RGS2 could suppress GPCR signalling even if p44/42 MAPK is activated via alternative routes. Furthermore, intracellular signalling is compartmentalized by spatial restriction mechanisms such as immobilization in lipid rafts [50,51] or attachment to scaffold proteins [52,53], and RGS2 could block phosphorylation of the GPCR signalling-associated p44/42 MAPK pool without affecting other pools. Thus p44/42 MAPK activity could be high in a tumour, even if the GPCR-associated activity is low.
###end p 84
###begin title 85
Conclusion
###end title 85
###begin p 86
###xml 458 463 458 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RGS2 </italic>
###xml 481 486 481 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OXTR </italic>
###xml 79 84 <span type="species:ncbi:10090">mouse</span>
We have confirmed and extended our previous analyses of prospectively isolated mouse mammary epithelial subpopulations by demonstrating that different levels of 33A10 antibody staining identify different luminal epithelial subpopulations. Furthermore, molecular analysis of prospectively isolated mammary epithelial cells has identified Rgs2 as a modulator of oxytocin receptor signalling that is expressed most strongly in the myoepithelial cell layer. The RGS2 gene, but not the OXTR gene, was also shown to be over-expressed in the majority of breast cancers, identifying the product of this gene, or the pathway(s) it regulates, as potentially significant therapeutic targets. However, because the function of RGS2 is unlikely to be mediated through oxytocin receptor signalling in breast cancer, its role in the pathogenesis of the disease remains to be elucidated.
###end p 86
###begin title 87
Abbreviations
###end title 87
###begin p 88
###xml 54 58 <span type="species:ncbi:9913">calf</span>
###xml 140 145 <span type="species:ncbi:9606">human</span>
EGFR = epidermal growth factor receptor; FCS = foetal calf serum; GAP = GTPase-activating protein; GPCR = G-protein coupled receptor; HER = human epidermal growth factor receptor; MAPK = mitogen-activated protein kinase; PBS = phosphate-buffered saline; qPCR = quantitative real time PCR; RGS2 = regulator of G-protein signalling 2; RT-PCR = reverse transcription polymerase chain reaction; SSC = sodium chloride/citrate.
###end p 88
###begin title 89
Competing interests
###end title 89
###begin p 90
The authors declare that they have no completing interests.
###end p 90
###begin title 91
Authors' contributions
###end title 91
###begin p 92
###xml 33 38 <span type="species:ncbi:10090">mouse</span>
###xml 573 578 <span type="species:ncbi:10090">mouse</span>
MJS designed the study, isolated mouse mammary cell populations, conducted biochemical analysis of RGS2 function, analyzed and interpreted the data, and drafted the manuscript. MI performed the microarray experiments and assisted with data analysis. ML performed and analysed the RT-PCR experiments on tumour samples. AG and TD carried out the bioinformatics analysis of the microarray data. HK and JLR performed the quantitative RT-PCR experiments and assisted with data analysis. KF and AM generated the in-house microarrays and assisted with data analysis. KB harvested mouse mammary fibroblasts and assisted with data analysis. SM and CJL helped design, carried out and interpreted siRNA knockdown assays. AA helped design the study and interpret the data and helped draft and revise the manuscript. All authors assisted with drafting the manuscript and approved the final version.
###end p 92
###begin title 93
Supplementary Material
###end title 93
###begin title 94
Additional file 1
###end title 94
###begin p 95
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 76 82 76 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 203 205 203 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
An .XLS file showing the results of cDNA microarray analysis of Sca-1+/33A10Low/- mammary cells with reference population. Genes are ranked by their M ratio. Only well annotated genes with a significant P value (<0.05) are shown. SOURCE Clone ID [54], UniGene ID, gene name and gene symbol are also given for each gene.
###end p 95
###begin p 96
Click here for file
###end p 96
###begin title 97
Additional file 2
###end title 97
###begin p 98
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 76 81 76 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">High </sup>
###xml 202 204 202 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
An .XLS file showing the results of cDNA microarray analysis of Sca-1-/33A10High mammary cells with reference population. Genes are ranked by their M ratio. Only well annotated genes with a significant P value (<0.05) are shown. SOURCE Clone ID [54], UniGene ID, gene name and gene symbol are also given for each gene.
###end p 98
###begin p 99
Click here for file
###end p 99
###begin title 100
Additional file 3
###end title 100
###begin p 101
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 76 82 76 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Low/- </sup>
###xml 203 205 203 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
An .XLS file showing the results of cDNA microarray analysis of Sca-1-/33A10Low/- mammary cells with reference population. Genes are ranked by their M ratio. Only well annotated genes with a significant P value (<0.05) are shown. SOURCE Clone ID [54], UniGene ID, gene name and gene symbol are also given for each gene.
###end p 101
###begin p 102
Click here for file
###end p 102
###begin title 103
Additional file 4
###end title 103
###begin p 104
###xml 191 193 191 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
An .XLS file showing the results of cDNA microarray analysis of mammary fibroblasts with reference population. Genes are ranked by their M ratio. Only well annotated genes with a significant P value (<0.05) are shown. SOURCE Clone ID [54], UniGene ID, gene name and gene symbol are also given for each gene.
###end p 104
###begin p 105
Click here for file
###end p 105
###begin title 106
Additional file 5
###end title 106
###begin p 107
###xml 168 170 168 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
An .XLS file showing the comparison of cDNA microarray data of all significant genes across all cell populations. Genes are listed alphabetically and their M ratio and P value (<0.05) for each cell population are shown. SOURCE Clone ID [54], UniGene ID, gene name and gene symbol are also given for each gene.
###end p 107
###begin p 108
Click here for file
###end p 108
###begin title 109
Additional file 6
###end title 109
###begin p 110
A .TIFF file showing the Gene Ontology biological process analysis of microarray data. Presented is a graphical representation of percentages of genes involved in differing biological processes, as defined by Gene Ontology annotation, for each cell population.
###end p 110
###begin p 111
Click here for file
###end p 111
###begin title 112
Acknowledgements
###end title 112
###begin p 113
The authors would like to thank Arnoud Sonnenberg for the kind gift of 33A10 antibody, Mike Allen for the gift of 1089M RNA, Parmjit Jat for the gift of 226L cells and Mike O'Hare for the gift of cell line and breast tumour RNA. They would also like to thank Ian Titley, Frederik Wallberg and Fiona-Ann Magnay for technical assistance. This work was funded by Breakthrough Breast Cancer. Kara Britt is funded by a Garvan Fellowship.
###end p 113
###begin article-title 114
Endocrine-responsive breast cancer and strategies for combating resistance
###end article-title 114
###begin article-title 115
###xml 43 48 <span type="species:ncbi:9606">human</span>
Development and potential clinical uses of human prolactin receptor antagonists
###end article-title 115
###begin article-title 116
ErbBs in mammary development
###end article-title 116
###begin article-title 117
The oxytocin receptor
###end article-title 117
###begin article-title 118
Oxytocin and oxytocin receptors in cancer cells and proliferation
###end article-title 118
###begin article-title 119
###xml 53 58 <span type="species:ncbi:9606">human</span>
Investigation of the oxytocin receptor expression in human breast cancer tissue using newly established monoclonal antibodies
###end article-title 119
###begin article-title 120
Immunolocalization and gene expression of oxytocin receptors in carcinomas and non-neoplastic tissues of the breast
###end article-title 120
###begin article-title 121
###xml 46 51 <span type="species:ncbi:9606">human</span>
Estrogen responsiveness and control of normal human breast proliferation
###end article-title 121
###begin article-title 122
The role of prolactin and growth hormone in mammary gland development
###end article-title 122
###begin article-title 123
Stem cells and breast cancer: a field in transit
###end article-title 123
###begin article-title 124
Generation of a functional mammary gland from a single stem cell
###end article-title 124
###begin article-title 125
###xml 17 22 <span type="species:ncbi:10090">mouse</span>
CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells
###end article-title 125
###begin article-title 126
Purification and unique properties of mammary epithelial stem cells
###end article-title 126
###begin article-title 127
Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland
###end article-title 127
###begin article-title 128
###xml 15 20 <span type="species:ncbi:10090">mouse</span>
Development of mouse mammary gland: identification of stages in differentiation of luminal and myoepithelial cells using monoclonal antibodies and polyvalent antiserum against keratin
###end article-title 128
###begin article-title 129
###xml 42 47 <span type="species:ncbi:10090">mouse</span>
Oncogene expression during progression of mouse mammary tumor cells; activity of a proviral enhancer and the resulting expression of int-2 is influenced by the state of differentiation
###end article-title 129
###begin article-title 130
###xml 27 32 <span type="species:ncbi:10090">mouse</span>
Clonal characterization of mouse mammary luminal epithelial and myoepithelial cells separated by fluorescence-activated cell sorting
###end article-title 130
###begin article-title 131
###xml 29 34 <span type="species:ncbi:10090">mouse</span>
Differentiation of separated mouse mammary luminal epithelial and myoepithelial cells cultured on EHS matrix analyzed by indirect immunofluorescence of cytoskeletal antigens
###end article-title 131
###begin article-title 132
FlowJo (Treestar Inc)
###end article-title 132
###begin article-title 133
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
Verification and initial annotation of the NIA mouse 15 K cDNA clone set
###end article-title 133
###begin article-title 134
###xml 85 90 <span type="species:ncbi:10090">mouse</span>
Genome-wide expression profiling of mid-gestation placenta and embryo using a 15,000 mouse developmental cDNA microarray
###end article-title 134
###begin article-title 135
Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation
###end article-title 135
###begin article-title 136
Linear models and empirical Bayes methods for assessing differential expression in microarray experiments
###end article-title 136
###begin article-title 137
R-project
###end article-title 137
###begin article-title 138
Bioconductor
###end article-title 138
###begin article-title 139
More powerful procedures for multiple significance testing
###end article-title 139
###begin article-title 140
Minimum information about a microarray experiment (MIAME)-toward standards for microarray data
###end article-title 140
###begin article-title 141
ArrayExpress
###end article-title 141
###begin article-title 142
###xml 79 84 <span type="species:ncbi:9606">human</span>
Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data
###end article-title 142
###begin article-title 143
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 138 142 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
Analysis of proviral integration in human mammary epithelial cell lines immortalized by retroviral infection with a temperature-sensitive SV40 T-antigen construct
###end article-title 143
###begin article-title 144
###xml 44 49 <span type="species:ncbi:9606">human</span>
Acquisition of tumorigenic potential in the human myoepithelial HBL100 cell line is associated with decreased expression of HLA class I, class II and integrin beta 3 and increased expression of c-myc
###end article-title 144
###begin article-title 145
###xml 48 53 <span type="species:ncbi:9606">human</span>
Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells
###end article-title 145
###begin article-title 146
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
###end article-title 146
###begin article-title 147
###xml 50 55 <span type="species:ncbi:9606">human</span>
Demonstration of functional oxytocin receptors in human breast Hs578T cells and their up-regulation through a protein kinase C-dependent pathway
###end article-title 147
###begin article-title 148
Error bars in experimental biology
###end article-title 148
###begin article-title 149
Oxytocin receptor elicits different EGFR/MAPK activation patterns depending on its localization in caveolin-1 enriched domains
###end article-title 149
###begin article-title 150
Fluorescent indicators for cytosolic calcium based on rhodamine and fluorescein chromophores
###end article-title 150
###begin article-title 151
RGS2: a multifunctional regulator of G-protein signaling
###end article-title 151
###begin article-title 152
Hormones and calcium: mechanisms controlling uterine smooth muscle contractile activity. The Litchfield Lecture
###end article-title 152
###begin article-title 153
Segregation of heterotrimeric G proteins in cell surface microdomains. G(q) binds caveolin to concentrate in caveolae, whereas G(i) and G(s) target lipid rafts by default
###end article-title 153
###begin article-title 154
###xml 71 75 <span type="species:ncbi:10090">mice</span>
Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice
###end article-title 154
###begin article-title 155
G-protein-coupled receptors and cancer
###end article-title 155
###begin article-title 156
Multi-tasking RGS proteins in the heart: the next therapeutic target?
###end article-title 156
###begin article-title 157
Regulation of T cell activation, anxiety, and male aggression by RGS2
###end article-title 157
###begin article-title 158
Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression
###end article-title 158
###begin article-title 159
G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival
###end article-title 159
###begin article-title 160
G protein-coupled receptors provide survival signals in prostate cancer
###end article-title 160
###begin article-title 161
The concept of synthetic lethality in the context of anticancer therapy
###end article-title 161
###begin article-title 162
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
###end article-title 162
###begin article-title 163
The role of lipid rafts in signalling and membrane trafficking in T lymphocytes
###end article-title 163
###begin article-title 164
Lipid rafts and signal transduction
###end article-title 164
###begin article-title 165
When kinases meet mathematics: the systems biology of MAPK signalling
###end article-title 165
###begin article-title 166
Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling
###end article-title 166
###begin article-title 167
SOURCE Database
###end article-title 167

